MCID: CNN002
MIFTS: 44

Cannabis Abuse

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

MalaCards integrated aliases for Cannabis Abuse:

Name: Cannabis Abuse 12 54 15 71
Marijuana Abuse 12 54 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9505
ICD9CM 34 305.2
MeSH 43 D002189
SNOMED-CT 67 37344009
ICD10 32 F12 F12.1
UMLS 71 C0006868 C0024809

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cyclic vomiting syndrome and conduct disorder. An important gene associated with Cannabis Abuse is CNR2 (Cannabinoid Receptor 2), and among its related pathways/superpathways are Signaling by GPCR and Neuroscience. The drugs Topiramate and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Cannabis Abuse

Diseases related to Cannabis Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 cyclic vomiting syndrome 30.3 OPRM1 CNR1
2 conduct disorder 30.0 DRD4 DRD2 COMT
3 polysubstance abuse 29.9 FAAH DRD2 COMT CNR1
4 personality disorder 29.9 DRD4 DRD2 COMT BDNF
5 drug dependence 29.6 OPRM1 DRD2 CNR1 BDNF
6 antisocial personality disorder 29.5 WASF2 WASF1 DRD4 DRD2 COMT
7 cocaine dependence 29.5 OPRM1 DRD2 COMT CNR1
8 alcohol use disorder 29.5 WASF2 WASF1 OPRM1 DRD2 COMT BDNF
9 panic disorder 29.5 DRD4 DRD2 COMT BDNF
10 withdrawal disorder 29.3 SPICE1 OPRM1 FAAH DRD2 CNR1
11 substance abuse 29.2 WASF2 WASF1 OPRM1 DRD4 DRD2 COMT
12 anxiety 28.8 OPRM1 NGF FAAH DRD4 DRD2 COMT
13 mood disorder 28.7 NRG1 DRD4 DRD2 COMT BDNF
14 alcohol dependence 28.6 OPRM1 NGF FAAH DRD4 DRD2 COMT
15 substance dependence 28.6 WASF2 WASF1 OPRM1 DRD4 DRD2 COMT
16 attention deficit-hyperactivity disorder 28.5 OPRM1 NGF DRD4 DRD2 DAGLA COMT
17 psychotic disorder 28.4 OPRM1 NRG1 DRD4 DRD2 COMT CNR1
18 bipolar disorder 28.4 NRG1 NGF DRD4 DRD2 COMT CNR1
19 cannabis dependence 28.3 WASF2 WASF1 SPICE1 SPATA6 NRG1 MGLL
20 schizophrenia 27.8 OPRM1 NRG1 NGF FAAH DRD4 DRD2
21 neurotrophic keratoconjunctivitis 10.4 NGF BDNF
22 autoimmune encephalitis 10.4 FAAH CNR1
23 adrenal gland pheochromocytoma 10.4 NGF BDNF
24 early-onset schizophrenia 10.4 DRD2 BDNF
25 histrionic personality disorder 10.3 WASF2 WASF1
26 narcissistic personality disorder 10.3 WASF2 WASF1
27 paranoid personality disorder 10.3 WASF2 WASF1
28 pyromania 10.3 WASF1 DRD2
29 dysthymic disorder 10.3 WASF2 WASF1 BDNF
30 paranoid schizophrenia 10.3 COMT CNR1 BDNF
31 tardive dyskinesia 10.2 DRD2 COMT
32 obsessive-compulsive personality disorder 10.2 WASF2 WASF1 COMT
33 phobia, specific 10.2 WASF2 WASF1 COMT
34 diabetic encephalopathy 10.2 NGF BDNF
35 cocaine abuse 10.2 NGF DRD2 BDNF
36 traumatic brain injury 10.2 DRD2 COMT BDNF
37 brain injury 10.2 DRD2 COMT BDNF
38 endogenous depression 10.2 WASF1 COMT BDNF
39 schizoid personality disorder 10.2 WASF2 WASF1 DRD2
40 borderline personality disorder 10.2 DRD2 COMT BDNF
41 intermittent explosive disorder 10.2 DRD2 COMT
42 tendinosis 10.2 CNR1 BDNF
43 generalized anxiety disorder 10.1 DRD2 COMT BDNF
44 severe combined immunodeficiency 10.1
45 agoraphobia 10.1 WASF2 WASF1 COMT BDNF
46 chronic cystitis 10.1 NGF BDNF
47 amphetamine abuse 10.1 DRD4 CNR1
48 dependent personality disorder 10.1 WASF2 WASF1 DRD4
49 visual epilepsy 10.0
50 seizure disorder 10.0

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 BAZ2B BDNF CNR1 COMT DAGLA DRD2
2 behavior/neurological MP:0005386 10.11 BDNF CNR1 COMT DAGLA DRD2 DRD4
3 digestive/alimentary MP:0005381 9.87 BDNF CNR1 DAGLA DRD2 OPRM1 WASF1
4 integument MP:0010771 9.81 BAZ2B BDNF CNR1 CNR2 DRD2 FAAH
5 nervous system MP:0003631 9.77 BDNF CNR1 COMT DAGLA DRD2 DRD4
6 no phenotypic analysis MP:0003012 9.17 BDNF CNR1 DRD2 MGLL NAPEPLD NGF

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
4
Clozapine Approved Phase 4 5786-21-0 2818
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Ondansetron Approved Phase 4 99614-02-5 4595
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12 Hypoglycemic Agents Phase 4
13 Anticonvulsants Phase 4
14 Anti-Anxiety Agents Phase 4
15 Serotonin Receptor Agonists Phase 4
16 Antipsychotic Agents Phase 4
17 Antidepressive Agents Phase 4
18 Quetiapine Fumarate Phase 4 111974-72-2
19 Dopamine Antagonists Phase 4
20 Nicotinic Agonists Phase 4
21 Cholinergic Agents Phase 4
22 Gastrointestinal Agents Phase 4
23 Antiemetics Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Serotonin Uptake Inhibitors Phase 4
26 Dermatologic Agents Phase 4
27 Haloperidol decanoate Phase 4
28 Hydrocortisone 17-butyrate 21-propionate Phase 4
29 Hydrocortisone hemisuccinate Phase 4
30 Estradiol 17 beta-cypionate Phase 4
31 Estradiol 3-benzoate Phase 4
32 Neurotransmitter Agents Phase 4
33 Adrenergic Agents Phase 4
34 Atomoxetine Hydrochloride Phase 4
35
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
36
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
37
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
38
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
39
Diphenhydramine Approved, Investigational Phase 2, Phase 3 58-73-1, 147-24-0 3100
40
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
41
Amphetamine Approved, Illicit, Investigational Phase 2, Phase 3 300-62-9 5826 3007
42
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
43
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
44
Peppermint oil Approved, Investigational Phase 3 8006-90-4
45
Peppermint Approved Phase 3
46
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
47
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
48
Vortioxetine Approved, Investigational Phase 2, Phase 3 508233-74-7 9966051
49
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
50
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803

Interventional clinical trials:

(show top 50) (show all 342)
# Name Status NCT ID Phase Drugs
1 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Unknown status NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
2 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
3 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
4 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
5 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
6 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Completed NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
8 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
9 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
10 Effects of Cortisol and Estradiol on the Pharmacokinetics of Tetrahydrocannabinol in Women Not yet recruiting NCT04374773 Phase 4 Dronabinol
11 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
12 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
13 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
14 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
15 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
16 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
17 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
18 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
19 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
20 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
21 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
22 A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury. Completed NCT01606189 Phase 3 GW-1000-02;GW-2000-02;Placebo
23 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
24 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
25 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Completed NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
26 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
27 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
28 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Completed NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
29 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
30 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
31 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Recruiting NCT03481959 Phase 3 Methylphenidate
32 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
33 Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study- Terminated NCT01071135 Phase 3 Quetiapine XR
34 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
35 Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
36 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
37 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
38 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
39 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
40 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
41 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
42 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
43 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT00350285 Phase 2
44 Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment Completed NCT00142961 Phase 2 Atomoxetine
45 A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence Completed NCT00360191 Phase 2 Buspirone
46 A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
47 The Effect of Prescription Medications in Marijuana Users Completed NCT00893074 Phase 1, Phase 2 Dronabinol 30mg/day;Dronabinol 60mg/day;Dronabinol 120mg/day;Placebo
48 Gabapentin for Cannabis Withdrawal and Use Completed NCT00395044 Phase 2 Placebo;Gabapentin
49 Effects of Bupropion on Marijuana Withdrawal Symptoms Completed NCT00142870 Phase 2 Bupropion
50 Effects of Dronabinol (Oral THC) on Cannabis Use Completed NCT01394185 Phase 1, Phase 2 Dronabinol 120mg/day;Placebo;Dronabinol 240mg/day

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

40
Brain, Testes, Eye, Lung, Cortex, Spinal Cord, Breast

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 726)
# Title Authors PMID Year
1
Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. 54 61
16540246 2006
2
Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. 61 54
15500971 2004
3
What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. 61
32485547 2020
4
Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. 61
32379627 2020
5
Cannabis Abuse or Dependence and Post-operative Outcomes After Appendectomy and Cholecystectomy. 61
32570125 2020
6
Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. 61
32329240 2020
7
Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations. 61
32494541 2020
8
Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department. 61
32426664 2020
9
Rates, predictors and the impact of cannabis misuse on in-hospital outcomes among patients undergoing percutaneous coronary intervention (from the National Inpatient Sample). 61
31922638 2020
10
Prevalence and associated factors of cannabis consumption in medical students: the BOURBON nationwide study. 61
32372364 2020
11
Coping Strategies and Factors Related to Problematic Substance Use and Behavioral Addictions Among Adolescents and Young Adults with Cancer. 61
32255742 2020
12
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. 61
31789638 2020
13
Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. 61
31808250 2020
14
Systemic administration with tetrahydrocannabinol causes retinal damage in BALB/c mice. 61
31680560 2020
15
Guided web-based treatment program for reducing cannabis use: a randomized controlled trial. 61
32070417 2020
16
Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. 61
31916333 2020
17
Intracerebellar Hemorrhage in a Young Adult. 61
32148353 2020
18
Modeling the Comorbidity of Cannabis Abuse and Conduct Disorder/Conduct Problems from a Cognitive Neuroscience Perspective. 61
31608811 2020
19
Epileptic Spikes in EEG and Migraine Attacks in the Course of Cannabis Withdrawal: A Case Report. 61
31741395 2020
20
Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers: A case-control study. 61
32226050 2020
21
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 61
30627731 2020
22
Disappearance of Tramadol and THC-COOH in Hair After Discontinuation of Abuse. Two Different Profiles. 61
30715334 2020
23
Analysis of cannabinoids in urine samples of short-term and long-term consumers of hemp seed products. 61
31670217 2019
24
[Cannabis, Cannabinoids and Cannabis Use Disorders]. 61
31847034 2019
25
Brain activation to cannabis- and alcohol-related words in alcohol use disorder. 61
31715379 2019
26
Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. 61
31698323 2019
27
Older Adults Driving Under the Influence: Associations With Marijuana Use, Marijuana Use Disorder, and Risk Perceptions. 61
29199501 2019
28
Affective and Substance Abuse Disorders Following Abortion by Pregnancy Intention in the United States: A Longitudinal Cohort Study. 61
31731786 2019
29
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. 61
30239074 2019
30
Regular cannabis use, with and without tobacco co-use, is associated with respiratory disease. 61
31557578 2019
31
The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: cannabis may have a greater impact in non-tobacco smokers. 61
31743053 2019
32
Relationships between Problematic Cannabis Use and Risky Behaviors in Spanish Adolescents. 61
31438581 2019
33
Threat Responsiveness as a Function of Cannabis and Alcohol Use Disorder Severity. 61
31170004 2019
34
Cannabis Abuse and Elevated Risk of Myocardial Infarction in the Young: A Population-Based Study. 61
31378243 2019
35
Cannabis Smoking-induced Diffuse Alveolar Hemorrhage. 61
31511809 2019
36
Demographic, Cannabis Use, and Depressive Correlates of Cannabis Use Consequences in Regular Cannabis Users. 61
31016818 2019
37
Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. 61
30790675 2019
38
Sexual orientation and mental health over the life course in a birth cohort. 61
31190681 2019
39
Neuregulin-1 is increased in schizophrenia patients with chronic cannabis abuse: Preliminary results. 61
30799217 2019
40
Cannabis abuse and dependence in kidney transplant candidates. 61
31003856 2019
41
Marijuana Induced Sick Sinus Syndrome: A Case Report. 61
31227686 2019
42
Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. 61
30448107 2019
43
Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. 61
31092662 2019
44
Marijuana smoking and markers of testicular function among men from a fertility centre. 61
30726923 2019
45
Trace Detection of Tetrahydrocannabinol in Body Fluid via Surface-Enhanced Raman Scattering and Principal Component Analysis. 61
30907578 2019
46
The relationship between motivations for cannabis consumption and problematic use. 61
31018002 2019
47
Differential dysfunctions related to alcohol and cannabis use disorder symptoms in reward and error-processing neuro-circuitries in adolescents. 61
30710868 2019
48
Context matters: Characteristics of solitary versus social cannabis use. 61
30779237 2019
49
[Risk factors for the development of schizophrenia]. 61
30802921 2019
50
Cannabinoids Identification in Lung Tissues of Young Cannabis Smokers Operated for Primary Spontaneous Pneumothorax and Correlation with Pathologic Findings. 61
31600764 2019

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

Pathways related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 WASF2 WASF1 OPRM1 NRG1 NGF NAPEPLD
2 12.25 OPRM1 NGF DAGLA COMT CNR1
3
Show member pathways
12.06 WASF2 WASF1 NRG1 NGF BDNF
4 11.62 GPR55 DRD4 CNR1
5
Show member pathways
11.62 OPRM1 NAPEPLD MGLL FAAH DAGLA CNR1
6 10.78 FAAH CNR2 CNR1
7 10.52 DAGLA CNR1
8
Show member pathways
10.49 DRD4 DRD2 COMT

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 OPRM1 NRG1 GPR55 DRD4 DRD2 CNR2
2 GABA-ergic synapse GO:0098982 9.5 NRG1 DRD2 CNR1
3 dendrite GO:0030425 9.5 OPRM1 NGF DRD4 DRD2 COMT CNR2
4 integral component of presynaptic membrane GO:0099056 9.43 OPRM1 DRD2 CNR1
5 SCAR complex GO:0031209 9.37 WASF2 WASF1
6 integral component of postsynaptic membrane GO:0099055 9.33 OPRM1 DRD2 DAGLA
7 axon GO:0030424 9.17 OPRM1 NRG1 NGF DRD2 COMT CNR1

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.88 OPRM1 COMT CNR2 CNR1
2 lipid catabolic process GO:0016042 9.86 NAPEPLD MGLL DAGLA
3 response to ethanol GO:0045471 9.85 OPRM1 DRD2 CNR1
4 locomotory behavior GO:0007626 9.84 OPRM1 NRG1 DRD2
5 modulation of chemical synaptic transmission GO:0050804 9.83 NGF DRD2 BDNF
6 memory GO:0007613 9.83 NGF CNR1 BDNF
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.8 WASF2 DRD2 CNR1
8 synapse assembly GO:0007416 9.79 NRG1 DRD2 BDNF
9 sensory perception of pain GO:0019233 9.77 OPRM1 CNR2 CNR1
10 response to cocaine GO:0042220 9.74 OPRM1 DRD2 CNR1
11 arachidonic acid metabolic process GO:0019369 9.7 MGLL FAAH DAGLA
12 behavioral response to cocaine GO:0048148 9.69 DRD4 DRD2
13 neurotrophin TRK receptor signaling pathway GO:0048011 9.69 NGF BDNF
14 response to amphetamine GO:0001975 9.69 DRD4 DRD2 CNR2
15 synaptic transmission, dopaminergic GO:0001963 9.68 DRD4 DRD2
16 nerve development GO:0021675 9.68 NGF BDNF
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD4 DRD2
18 regulation of synaptic transmission, GABAergic GO:0032228 9.67 DRD2 CNR1
19 negative regulation of nitric-oxide synthase activity GO:0051001 9.66 CNR2 CNR1
20 nerve growth factor signaling pathway GO:0038180 9.66 NGF BDNF
21 dendrite extension GO:0097484 9.65 WASF1 BDNF
22 inhibitory postsynaptic potential GO:0060080 9.64 DRD4 BDNF
23 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.64 WASF2 WASF1
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD4 DRD2
25 positive regulation of collateral sprouting GO:0048672 9.62 NGF BDNF
26 monoacylglycerol catabolic process GO:0052651 9.61 MGLL FAAH
27 negative regulation of synaptic transmission, GABAergic GO:0032229 9.61 CNR2 BDNF
28 regulation of sensory perception of pain GO:0051930 9.61 OPRM1 MGLL COMT
29 lamellipodium morphogenesis GO:0072673 9.59 WASF2 WASF1
30 negative regulation of mast cell activation GO:0033004 9.58 CNR2 CNR1
31 response to morphine GO:0043278 9.58 OPRM1 DRD2 CNR1
32 negative regulation of action potential GO:0045759 9.56 CNR2 CNR1
33 fear response GO:0042596 9.55 DRD4 BDNF
34 negative regulation of dopamine secretion GO:0033602 9.54 DRD2 CNR1
35 peripheral nervous system development GO:0007422 9.54 NRG1 NGF BDNF
36 regulation of metabolic process GO:0019222 9.5 CNR2 CNR1 BDNF
37 retrograde trans-synaptic signaling by endocannabinoid GO:0098921 9.49 DAGLA CNR1
38 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD4 DRD2
39 response to histamine GO:0034776 9.46 DRD4 DRD2
40 behavioral response to ethanol GO:0048149 9.43 OPRM1 DRD4 DRD2
41 dopamine metabolic process GO:0042417 9.33 DRD4 DRD2 COMT
42 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.26 OPRM1 DRD4 CNR2 CNR1
43 cannabinoid signaling pathway GO:0038171 8.8 GPR55 CNR2 CNR1

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 OPRM1 GPR55 DRD4 DRD2 CNR2 CNR1
2 drug binding GO:0008144 9.5 DRD4 DRD2 CNR1
3 Arp2/3 complex binding GO:0071933 9.46 WASF2 WASF1
4 dopamine binding GO:0035240 9.43 DRD4 DRD2
5 acylglycerol lipase activity GO:0047372 9.4 MGLL FAAH
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD4 DRD2
7 nerve growth factor receptor binding GO:0005163 9.16 NGF BDNF
8 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD4 DRD2
9 cannabinoid receptor activity GO:0004949 8.8 GPR55 CNR2 CNR1

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....